SEC Comment Letter 0000000000-23-003858 to Tarsus Pharmaceuticals, Inc. (TARS) (CIK 0001819790) (TARS)
Tarsus Pharmaceuticals, Inc. (TARS) (CIK 0001819790)
Date: April 18, 2023 · CIK: 0001819790 · Accession: 0000000000-23-003858
AI Filing Summary & Sentiment
File numbers found in text: 001-39614
Letter
United States securities and exchange commission logo April 18, 2023 Leonard Greenstein Chief Financial Officer Tarsus Pharmaceuticals, Inc. 15440 Laguna Canyon Road Suite 160 Irvine, California 92618 Re:Tarsus Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed March 17, 2023 File No. 001-39614 Dear Leonard Greenstein: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
April 18, 2023
Leonard Greenstein
Chief Financial Officer
Tarsus Pharmaceuticals, Inc.
15440 Laguna Canyon Road
Suite 160
Irvine, California 92618
Re:Tarsus Pharmaceuticals, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2022
Filed March 17, 2023
File No. 001-39614
Dear Leonard Greenstein:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences